Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases

Dermatitis. 2012 Sep-Oct;23(5):237-8. doi: 10.1097/DER.0b013e31826e45d7.

Abstract

A wide spectrum of skin toxicities has been described in patients receiving epidermal growth factor receptor (EGFR), inhibitors, including papulopustular rash, xerosis and fissures, pruritus, mucositis, paronychia, and hair changes.Trichomegaly of the eyelashes is a rare adverse effect of EGFR inhibitor therapy and is characterized by a paradoxical overgrowth of eyelashes. We present 3 cases of trichomegaly occurred during EGFR inhibitor therapy.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Drug Eruptions / etiology*
  • ErbB Receptors / antagonists & inhibitors*
  • Erlotinib Hydrochloride
  • Exanthema / chemically induced
  • Eyelashes
  • Female
  • Hair Diseases / chemically induced*
  • Humans
  • Middle Aged
  • Panitumumab
  • Quinazolines / adverse effects*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Quinazolines
  • Panitumumab
  • Erlotinib Hydrochloride
  • ErbB Receptors